Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
08 2023
Historique:
received: 19 11 2022
revised: 22 04 2023
accepted: 22 04 2023
medline: 31 7 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several patients with Rett syndrome. The aim of this study was to explore whether MECP2 variants are associated with an idiopathic central precocious puberty phenotype. In this translational cohort study, participants were recruited from seven tertiary centres from five countries (Brazil, Spain, France, the USA, and the UK). Patients with idiopathic central precocious puberty were investigated for rare potentially damaging variants in the MECP2 gene, to assess whether MECP2 might contribute to the cause of central precocious puberty. Inclusion criteria were the development of progressive pubertal signs (Tanner stage 2) before the age of 8 years in girls and 9 years in boys and basal or GnRH-stimulated LH pubertal concentrations. Exclusion criteria were the diagnosis of peripheral precocious puberty and the presence of any recognised cause of central precocious puberty (CNS lesions, known monogenic causes, genetic syndromes, or early exposure to sex steroids). All patients included were followed up at the outpatient clinics of participating academic centres. We used high-throughput sequencing in 133 patients and Sanger sequencing of MECP2 in an additional 271 patients. Hypothalamic expression of Mecp2 and colocalisation with GnRH neurons were determined in mice to show expression of Mecp2 in key nuclei related to pubertal timing regulation. Between Jun 15, 2020, and Jun 15, 2022, 404 patients with idiopathic central precocious puberty (383 [95%] girls and 21 [5%] boys; 261 [65%] sporadic cases and 143 [35%] familial cases from 134 unrelated families) were enrolled and assessed. We identified three rare heterozygous likely damaging coding variants in MECP2 in five girls: a de novo missense variant (Arg97Cys) in two monozygotic twin sisters with central precocious puberty and microcephaly; a de novo missense variant (Ser176Arg) in one girl with sporadic central precocious puberty, obesity, and autism; and an insertion (Ala6_Ala8dup) in two unrelated girls with sporadic central precocious puberty. Additionally, we identified one rare heterozygous 3'UTR MECP2 insertion (36_37insT) in two unrelated girls with sporadic central precocious puberty. None of them manifested Rett syndrome. Mecp2 protein colocalised with GnRH expression in hypothalamic nuclei responsible for GnRH regulation in mice. We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this crucial biological process. Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and the Wellcome Trust.

Sections du résumé

BACKGROUND
Identification of genetic causes of central precocious puberty have revealed epigenetic mechanisms as regulators of human pubertal timing. MECP2, an X-linked gene, encodes a chromatin-associated protein with a role in gene transcription. MECP2 loss-of-function mutations usually cause Rett syndrome, a severe neurodevelopmental disorder. Early pubertal development has been shown in several patients with Rett syndrome. The aim of this study was to explore whether MECP2 variants are associated with an idiopathic central precocious puberty phenotype.
METHODS
In this translational cohort study, participants were recruited from seven tertiary centres from five countries (Brazil, Spain, France, the USA, and the UK). Patients with idiopathic central precocious puberty were investigated for rare potentially damaging variants in the MECP2 gene, to assess whether MECP2 might contribute to the cause of central precocious puberty. Inclusion criteria were the development of progressive pubertal signs (Tanner stage 2) before the age of 8 years in girls and 9 years in boys and basal or GnRH-stimulated LH pubertal concentrations. Exclusion criteria were the diagnosis of peripheral precocious puberty and the presence of any recognised cause of central precocious puberty (CNS lesions, known monogenic causes, genetic syndromes, or early exposure to sex steroids). All patients included were followed up at the outpatient clinics of participating academic centres. We used high-throughput sequencing in 133 patients and Sanger sequencing of MECP2 in an additional 271 patients. Hypothalamic expression of Mecp2 and colocalisation with GnRH neurons were determined in mice to show expression of Mecp2 in key nuclei related to pubertal timing regulation.
FINDINGS
Between Jun 15, 2020, and Jun 15, 2022, 404 patients with idiopathic central precocious puberty (383 [95%] girls and 21 [5%] boys; 261 [65%] sporadic cases and 143 [35%] familial cases from 134 unrelated families) were enrolled and assessed. We identified three rare heterozygous likely damaging coding variants in MECP2 in five girls: a de novo missense variant (Arg97Cys) in two monozygotic twin sisters with central precocious puberty and microcephaly; a de novo missense variant (Ser176Arg) in one girl with sporadic central precocious puberty, obesity, and autism; and an insertion (Ala6_Ala8dup) in two unrelated girls with sporadic central precocious puberty. Additionally, we identified one rare heterozygous 3'UTR MECP2 insertion (36_37insT) in two unrelated girls with sporadic central precocious puberty. None of them manifested Rett syndrome. Mecp2 protein colocalised with GnRH expression in hypothalamic nuclei responsible for GnRH regulation in mice.
INTERPRETATION
We identified rare MECP2 variants in girls with central precocious puberty, with or without mild neurodevelopmental abnormalities. MECP2 might have a role in the hypothalamic control of human pubertal timing, adding to the evidence of involvement of epigenetic and genetic mechanisms in this crucial biological process.
FUNDING
Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and the Wellcome Trust.

Identifiants

pubmed: 37385287
pii: S2213-8587(23)00131-6
doi: 10.1016/S2213-8587(23)00131-6
pmc: PMC7615084
mid: EMS187253
pii:
doi:

Substances chimiques

Follicle Stimulating Hormone 9002-68-0
Gonadotropin-Releasing Hormone 33515-09-2
Luteinizing Hormone 9002-67-9
MECP2 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-554

Subventions

Organisme : NICHD NIH HHS
ID : R00 HD091381
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00006/2
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R21 HD098684
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R01 HD082314
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Hum Mol Genet. 2007 Mar 15;16(6):640-50
pubmed: 17309881
Ann Neurol. 2010 Dec;68(6):944-50
pubmed: 21154482
Hum Reprod. 2021 Jan 25;36(2):506-518
pubmed: 33313884
Eur J Endocrinol. 2021 Oct 08;185(5):617-627
pubmed: 34403359
Am J Hum Genet. 2001 May;68(5):1093-101
pubmed: 11309679
Pharmazie. 2021 Nov 1;76(11):559-561
pubmed: 34782041
Genet Med. 2020 Jul;22(7):1156-1174
pubmed: 32284538
Pediatr Neurol. 2014 Dec;51(6):769-75
pubmed: 25283752
N Engl J Med. 2013 Jun 27;368(26):2467-75
pubmed: 23738509
Science. 2008 May 30;320(5880):1224-9
pubmed: 18511691
Neural Plast. 2012;2012:415825
pubmed: 22474603
J Clin Endocrinol Metab. 2017 May 1;102(5):1557-1567
pubmed: 28324015
Endocr Rev. 2023 Mar 4;44(2):193-221
pubmed: 35930274
Natl Sci Rev. 2020 Mar;7(3):671-685
pubmed: 34692086
Nat Genet. 1999 Oct;23(2):185-8
pubmed: 10508514
Sci Rep. 2019 Aug 19;9(1):11983
pubmed: 31427717
Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R235-43
pubmed: 15358730
Sci Rep. 2020 Dec 17;10(1):22255
pubmed: 33335218
J Neuroendocrinol. 2009 Feb;21(2):108-22
pubmed: 19187398
Brain Sci. 2021 Jul 09;11(7):
pubmed: 34356138
Sci Rep. 2016 Jun 21;6:28295
pubmed: 27323888
Nat Genet. 2006 Jan;38(1):47-53
pubmed: 16341221
Lancet Diabetes Endocrinol. 2016 Mar;4(3):265-274
pubmed: 26852255
Hum Mol Genet. 2020 Sep 30;29(R1):R89-R99
pubmed: 32681172
Nature. 2010 Nov 11;468(7321):263-9
pubmed: 21068835
Epigenomics. 2015;7(2):247-65
pubmed: 25942534
Nat Commun. 2015 Aug 04;6:7756
pubmed: 26239645
Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5;144B(3):355-60
pubmed: 17171659
Front Genet. 2021 Jan 21;12:620859
pubmed: 33552148

Auteurs

Ana P M Canton (APM)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Flávia R Tinano (FR)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Leonardo Guasti (L)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Luciana R Montenegro (LR)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Fiona Ryan (F)

Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Deborah Shears (D)

Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Maria Edna de Melo (ME)

League of Childhood Obesity, University of Sao Paulo, Sao Paulo, Brazil.

Larissa G Gomes (LG)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Mariana P Piana (MP)

Children's State Hospital of Vila Velha, Vila Velha, Brazil.

Raja Brauner (R)

Fondation Ophtalmologique Adolphe de Rothschild and Université de Paris, Paris, France.

Rafael Espino-Aguilar (R)

Hospital Universitario Virgen de Valmes, Universidad de Sevilla, Sevilla, Spain.

Arancha Escribano-Muñoz (A)

Endocrinology Unit, Department of Pediatrics, Virgen de la Arrixaca University Hospital, Murcia, Spain.

Alyssa Paganoni (A)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Jordan E Read (JE)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Márta Korbonits (M)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Carlos E Seraphim (CE)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Silvia S Costa (SS)

Discipline of Endocrinology and Metabolism, Clinicas Hospital, School of Medicine and Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of Sao Paulo, Sao Paulo, Brazil.

Ana Cristina Krepischi (AC)

Discipline of Endocrinology and Metabolism, Clinicas Hospital, School of Medicine and Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of Sao Paulo, Sao Paulo, Brazil.

Alexander A L Jorge (AAL)

Genetic Endocrinology Unit LIM/25, University of Sao Paulo, Sao Paulo, Brazil.

Alessia David (A)

Centre for Integrative Systems Biology and Bioinformatics, Department of Life Sciences, Imperial College London, London, UK.

Lena R Kaisinger (LR)

Medical Research Council Epidemiology Unit, Wellcome-Medical Research Council Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.

Ken K Ong (KK)

Medical Research Council Epidemiology Unit, Wellcome-Medical Research Council Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.

John R B Perry (JRB)

Medical Research Council Epidemiology Unit, Wellcome-Medical Research Council Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.

Ana Paula Abreu (AP)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Ursula B Kaiser (UB)

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Jesús Argente (J)

Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, Spain; Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Instituto de Investigación La Princesa, Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, IMDEA Food Institute, Madrid, Spain.

Berenice B Mendonca (BB)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Vinicius N Brito (VN)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil.

Sasha R Howard (SR)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Department of Paediatric Endocrinology, Barts Health NHS Trust, London, UK.

Ana Claudia Latronico (AC)

Developmental Endocrinology Unit, Laboratory of Hormones and Molecular Genetics LIM/42, University of Sao Paulo, Sao Paulo, Brazil. Electronic address: anacl@usp.br.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH